Litigation Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-02-07 |
| Court | District Court, D. Delaware | Date Terminated | 2022-09-12 |
| Cause | 35:1 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Defendant | Referred To | |
| Parties | SHILPA MEDICARE LIMITED | ||
| Patents | 6,642,245; 6,703,396; 6,838,464; 7,125,879; 7,390,791; 7,803,788; 8,080,551; 8,101,629; 8,754,065; 9,296,769 | ||
| Attorneys | Karen L. Beckman | ||
| Firms | Smith, Katzenstein, & Jenkins LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Apotex, Inc.
Biologic Drugs cited in Gilead Sciences, Inc. v. Apotex, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-02-02 | 189 | Redacted Document | . Nor could it. Claim 1 of asserted U.S. Patent No. 8,754,065 claims “tenofovir alafenamide hemifumarate…to a date by which it will assert any additional patent claims. All of these reasons should be rejected…expiration of two of Gilead’s Orange Book-listed patents. (See D.I. 1 at ¶¶ 192-200.) On February 7, 2020…action against Shilpa for infringement of those two patents, which cover the particular pharmaceutical form…s drug substance with respect to any unasserted patent claims. (Id.) Finally, Shilpa | External link to document |
| 2021-04-01 | 201 | Notice of Service | Trout Regarding Claim Construction of U.S. Patent Nos. 7,390,791; 7,803,788; 8,754,065; and 9,296,769 filed… 12 September 2022 1:20-cv-00189 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
